Targeted drug delivery and theranostic strategies in malignant lymphomas
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F22%3A00552542" target="_blank" >RIV/61389013:_____/22:00552542 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/22:10440207 RIV/00064165:_____/22:10440207
Result on the web
<a href="https://www.mdpi.com/2072-6694/14/3/626" target="_blank" >https://www.mdpi.com/2072-6694/14/3/626</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/cancers14030626" target="_blank" >10.3390/cancers14030626</a>
Alternative languages
Result language
angličtina
Original language name
Targeted drug delivery and theranostic strategies in malignant lymphomas
Original language description
Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT) 131I-tositumomab and 90Y-ibritumomab-tiuxetan. The later clinical success of the first approved antibody–drug conjugate (ADC) for the treatment of lymphomas, anti-CD30 brentuximab vedotin, paved the path for the preclinical development and clinical testing of several other ADCs, including polatuzumab vedotin and loncastuximab tesirine. Other modalities of TDD are based on new formulations of “old” cytostatic agents and their passive trapping in the lymphoma tissue by means of the enhanced permeability and retention (EPR) effect. Currently, the diagnostic and restaging procedures in aggressive lymphomas are based on nuclear imaging, namely PET. A theranostic approach that combines diagnostic or restaging lymphoma imaging with targeted treatment represents an appealing innovative strategy in personalized medicine. The future of theranostics will require not only the capability to provide suitable disease-specific molecular probes but also expertise on big data processing and evaluation. Here, we review the concept of targeted drug delivery in malignant lymphomas from RIT and ADC to a wide array of passively and actively targeted nano-sized investigational agents. We also discuss the future of molecular imaging with special focus on monoclonal antibody-based and monoclonal antibody-derived theranostic strategies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10404 - Polymer science
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancers (Basel)
ISSN
2072-6694
e-ISSN
2072-6694
Volume of the periodical
14
Issue of the periodical within the volume
3
Country of publishing house
CH - SWITZERLAND
Number of pages
22
Pages from-to
626
UT code for WoS article
000756075900001
EID of the result in the Scopus database
2-s2.0-85123297330